{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang Q"],"funding":["NIDA NIH HHS","NIAID NIH HHS","NIAID","NIDA"],"pagination":["e0300524"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11025929"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(4)"],"pubmed_abstract":["To address the need for multivalent vaccines against Coronaviridae that can be rapidly developed and manufactured, we compared antibody responses against SARS-CoV, SARS-CoV-2, and several variants of concern in mice immunized with mRNA-lipid nanoparticle vaccines encoding homodimers or heterodimers of SARS-CoV/SARS-CoV-2 receptor-binding domains. All vaccine constructs induced robust anti-RBD antibody responses, and the heterodimeric vaccine elicited an IgG response capable of cross-neutralizing SARS-CoV, SARS-CoV-2 Wuhan-Hu-1, B.1.351 (beta), and B.1.617.2 (delta) variants."],"journal":["PloS one"],"pubmed_title":["Induction of neutralizing antibodies against SARS-CoV-2 variants by a multivalent mRNA-lipid nanoparticle vaccine encoding SARS-CoV-2/SARS-CoV Spike protein receptor-binding domains in mice."],"pmcid":["PMC11025929"],"funding_grant_id":["AI125103","DA046171","R01 DA049524","DA049524","R01 DA046171","R21 AI125103"],"pubmed_authors":["Li W","Wen J","Jokerst J","Wang S","Tiwari S","Rawling S","Rana TM","Zhang L","Zhang Q","Cheng Y","Wang L"],"additional_accession":[]},"is_claimable":false,"name":"Induction of neutralizing antibodies against SARS-CoV-2 variants by a multivalent mRNA-lipid nanoparticle vaccine encoding SARS-CoV-2/SARS-CoV Spike protein receptor-binding domains in mice.","description":"To address the need for multivalent vaccines against Coronaviridae that can be rapidly developed and manufactured, we compared antibody responses against SARS-CoV, SARS-CoV-2, and several variants of concern in mice immunized with mRNA-lipid nanoparticle vaccines encoding homodimers or heterodimers of SARS-CoV/SARS-CoV-2 receptor-binding domains. All vaccine constructs induced robust anti-RBD antibody responses, and the heterodimeric vaccine elicited an IgG response capable of cross-neutralizing SARS-CoV, SARS-CoV-2 Wuhan-Hu-1, B.1.351 (beta), and B.1.617.2 (delta) variants.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-05-29T11:26:00.717Z","creation":"2026-04-08T04:28:09.795Z"},"accession":"S-EPMC11025929","cross_references":{"pubmed":["38635805"],"doi":["10.1371/journal.pone.0300524"]}}